211 related articles for article (PubMed ID: 29411666)
21. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
22. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract][Full Text] [Related]
23. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
[TBL] [Abstract][Full Text] [Related]
24. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
25. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.
Alpermann T; Haferlach C; Eder C; Nadarajah N; Meggendorfer M; Kern W; Haferlach T; Schnittger S
Leuk Res; 2015 Mar; 39(3):265-72. PubMed ID: 25592059
[TBL] [Abstract][Full Text] [Related]
26. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
27. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
Fujino T
Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
[TBL] [Abstract][Full Text] [Related]
28. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
29. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
[TBL] [Abstract][Full Text] [Related]
30. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.
Cortes JE; Kantarjian H; O'Brien S; Keating M; Pierce S; Freireich EJ; Estey E
Leukemia; 1995 Jan; 9(1):115-7. PubMed ID: 7845005
[TBL] [Abstract][Full Text] [Related]
31. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
32. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.
Churpek JE; Pyrtel K; Kanchi KL; Shao J; Koboldt D; Miller CA; Shen D; Fulton R; O'Laughlin M; Fronick C; Pusic I; Uy GL; Braunstein EM; Levis M; Ross J; Elliott K; Heath S; Jiang A; Westervelt P; DiPersio JF; Link DC; Walter MJ; Welch J; Wilson R; Ley TJ; Godley LA; Graubert TA
Blood; 2015 Nov; 126(22):2484-90. PubMed ID: 26492932
[TBL] [Abstract][Full Text] [Related]
33. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
35. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
[TBL] [Abstract][Full Text] [Related]
36. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
[TBL] [Abstract][Full Text] [Related]
37. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
[TBL] [Abstract][Full Text] [Related]
38. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
39. [Cytogenetic and clinical analysis of -7/7q- abnormalities in acute leukemia and myelodysplastic syndrome].
Meng HT; Mai WY; Chen ZM; Lou JY; Jin J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Aug; 12(4):460-3. PubMed ID: 15363131
[TBL] [Abstract][Full Text] [Related]
40. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop.
Olney HJ; Mitelman F; Johansson B; Mrózek K; Berger R; Rowley JD
Genes Chromosomes Cancer; 2002 Apr; 33(4):413-23. PubMed ID: 11921275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
